BEDFORD, Mass.—Late October saw the launch of Verseau Therapeutics Inc., which hit the ground running with $50 million in financing from 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua Capital. The company's aim will be to develop novel, first-in-class immunotherapies that modulate macrophages, with the startup funding to help move its macrophage checkpoint modulator programs into the clinic. Verseau has a strategic collaboration in place with 3SBio, under which the latter gains an exclusive license to develop and commercialize a number of MCM antibodies for all human oncology indications in Greater China, including mainland China, Taiwan, Hong Kong and Macau. Verseau will retain all global rights.